9 results about "HBeAg" patented technology

The invention relates to application of an extracellular matrix protein 1 in preparation of a medicine for treating HBV infection, and belongs to the technical field of biological medicine. The invention provides application of an extracellular matrix protein 1 and / or an extracellular matrix protein 1 accelerant in preparation of drugs for preventing and / or treating HBV infection and related diseases caused by HBV infection. Experiments show that the intrahepatic overexpression extracellular matrix protein 1 can significantly reduce the level of HBsAg and HBeAg in an HBV mouse body and promote the generation of HBsAb in the HBV mouse body; meanwhile, the levels of HBsAg and HBeAg in the HBV mouse can also be remarkably reduced by utilizing the expression of the extracellular matrix protein 1 in the hepatic stellate cells of the HBV mouse and the exogenous supplement of the extracellular matrix protein 1 to the HBV mouse through the adeno-associated virus. Therefore, the extracellular matrix protein 1 can effectively promote the removal of HBV, and provides higher possibility for functional healing of HBV infection.

The invention provides application of a BTLA inhibitor in preparation of a medicine for preventing and / or treating chronic hepatitis B, and belongs to the technical field of biological medicine. Research finds that antagonistic B and T lymphocyte attenuation factors (BTLA) can promote removal of hepatitis B surface antigen (HBsAg), reduce the expression level of HBeAg, promote activation and proliferation of T cells and enhance host immune response, so that the purpose of preventing and / or treating chronic hepatitis B is achieved, and functional cure of chronic hepatitis B (CHB) is achieved. The invention provides more choices for medicines for clinically preventing and / or treating chronic hepatitis B.

The present application belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition with the effect of preventing and / or treating hepatitis B. The traditional Chinese medicine composition is mainly prepared from Notopterygium incisum, Angelica pubescens, Poria cocos, Saposhnikovia divaricata, Schizonepeta tenuifolia, Chuanxiong, Platycodon grandiflorum, Bupleurum chinense, Peucedanum praeruptorum, Citrus aurantium, and Glycyrrhiza uralensis. The traditional Chinese medicine composition can not only significantly inhibit the activity of hepatitis B virus, but also significantly inhibit the secretion of HBSAg and HBeAg of hepatitis B virus, inhibit rebound after drug withdrawal, has a significant preventive and / or therapeutic effect on liver damage caused by hepatitis B virus infection, and can promote the production of hepatitis B surface antibody, thus having a broad clinical application prospect.

The invention provides an antibody for resisting an asialoglycoprotein receptor as well as a preparation method and application of the antibody. The antibody for resisting the asialoglycoprotein receptor comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain variable region HCDR1-HCDR3; and the light chain variable region comprises a light chain variable region LCDR1-LCDR3. According to the present invention, the affinity of the anti-asialoglycoprotein receptor antibody to the human asialoglycoprotein receptor is 0.425 nM, and the antigen recognition ability is strong; the compound disclosed by the invention can be used for remarkably inhibiting the DNA expression of HBsAg, HBeAg and HBV of HepG2.2. 15 cells and HepAD38 cells, has a function of inhibiting the replication of the hepatitis B virus, and has a great application prospect in medicines for preventing and / or treating hepatitis B virus infection and / or preventing and / or treating related diseases caused by the hepatitis B virus infection.

The present disclosure provides an antisense oligonucleotide for reducing HBV gene expression and use thereof. The antisense oligonucleotide comprises a 5' wing, a central DNA region and a 3' wing; the antisense oligonucleotide satisfies one or more of the following conditions: (i) the nucleotide sequence of the 5' wing comprises the nucleotide sequence shown in any one of SEQ ID NOs: 181-186 or a modified sequence thereof; (ii) the nucleotide sequence of the central DNA region comprises the nucleotide sequence shown in any one of SEQ ID NOs: 13-18 or a modified sequence thereof; (iii) the nucleotide sequence of the 3' wing comprises the nucleotide sequence shown in any one of SEQ ID NOs: 189-194 or a modified sequence thereof. The antisense oligonucleotide of the present disclosure and / or the modified product thereof can significantly reduce the levels of HBsAg, HBeAg and HBV DNA in serum.

The invention discloses a nano antibody targeting a hepatitis B core antigen as well as a coding gene and application thereof, and relates to the technical field of biological medicines. The nano antibody comprises an amino acid sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 5, and can be specifically combined with HBcAg. The invention also relates to a coding nucleic acid, an expression vector, a host cell and a preparation method of the nano antibody, and application of the nano antibody in preparation of anti-hepatitis B virus drugs and diagnostic reagents. Experiments show that the nano antibody has high affinity of targeting HBcAg, can combine and destroy hepatitis B virus nucleocapsid assembly and inhibit secretion of virus proteins such as HBsAg, HBeAg and the like, and thus has good anti-hepatitis B virus activity.

The invention discloses an application of (R)-HTS-3 in preparation of a medicine for treating hepatitis B. The (R)-HTS-3 can inhibit the levels of HBsAg, HBeAg, HBc, 3.5 kb HBV RNA, HBV core-associated DNA and HBV cccDNA in HBV replication cells, namely can inhibit HBV replication, has low toxicity to hepatocytes, can be used for preparing the medicine for treating hepatitis B, and has a good clinical application prospect.

The application relates to application of extracellular matrix protein 1 in preparation of a medicine for treating HBV infection, and belongs to the technical field of biological medicine. The application provides application of extracellular matrix protein 1 and / or a promoter of extracellular matrix protein 1 in preparation of a medicine for preventing and / or treating HBV infection and diseases caused by the HBV infection. Experiments show that overexpression of the extracellular matrix protein 1 in the liver can significantly reduce the levels of HBsAg and HBeAg in HBV mice, and promote the production of HBsAb in the HBV mice; meanwhile, the expression of the extracellular matrix protein 1 in the liver stellate cells of the HBV mice is supplemented by using an adenovirus, and the extracellular matrix protein 1 is supplemented from outside, which can also significantly reduce the levels of HBsAg and HBeAg in the HBV mice. It can be seen that the extracellular matrix protein 1 can effectively promote the clearance of the HBV, and provide higher possibility for functional cure of the HBV infection.

Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and / or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.